Jeffrey S Elmendorf discusses the impact of cholesterol in type 2 diabetes and the latest findings from current studies.
1. Why is cholesterol of interest for metabolic health and disease? (0:07)
2. Is cellular cholesterol toxicity and type 2 diabetes risk supported by clinical findings? (0:50)
3. Are there data that explain the incidence of increased type 2 diabetes risk with statin therapy? (1:27)
4. How does pitavastatin differ in having a favorable impact on metabolic health? (3:18)
View the full article here.
Speaker disclosures: Jeffrey S Elmendorf has nothing to declare in relation to this video interview.
Support: The publication of this video was supported by Kowa Pharmaceuticals America who was given the opportunity to review the video for scientific accuracy before publication. Any resulting changes were made at the author’s/authors’ discretion.
Share this Video
Related Videos In Diabetes
Andrew Boulton, IDF 2021: Anticipated Congress Highlights
It was a pleasure to meet with IDF President, Prof. Andrew Boulton (University of Manchester, UK) ahead of this year’s virtual meeting to discuss anticipated congress highlights and the relationship between COVID-19 and diabetes. Questions What do you expect to be the highlights of this year’s IDF Congress? (0:20) What have we learned about the […]
IDF Virtual 2021 – Diabetes Complications and Covid-19
The International Diabetes Federation will organise a Virtual Congress on December 6-11, 2021. It will feature the latest research on diabetes complications and sessions dedicated to COVID-19 and diabetes, the centenary of insulin and the IDF Diabetes Atlas 10th Edition. Discover the Congress at https://idf2021.org
Matthew Budoff, ENDO 2021: Findings from a Substudy of the VERTIS CV Trial – Ertugliflozin for T2DM & ASCVD
We caught up with Professor Matthew Budoff (UCLA and Lundquist Institute, Torrance, CA, US) to discuss ertugliflozin in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea (Clinical Trial Identifier: NCT01986881). ‘Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!